04 Jun 2015 Posted in ABPI statement By Alison Clough
Alison Clough, Acting CEO and Executive Director – Commercial UK, said:
“The IPPR Report clearly articulates the barriers to innovation within the NHS, including those which are preventing the adoption and the use of innovative medicines across a range of major diseases. The impact on patients is dramatic - in the UK, patient access to new medicines is low and slow by international standards. For the first five years after the launch of a new medicine, people in the UK are significantly less likely to have access to new medicines than people living in other countries.
"The pharmaceutical industry is committed to removing barriers so patients get access to the medicines they need. We’d like to see the report’s recommendations for unleashing innovation within the NHS fuel further debate, contribute to the development of effective solutions and deliver improved patient outcomes within a healthcare system that is fit for the 21st century and beyond.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811